1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Cancer Diagnostics Market
2.2. Global Cancer Diagnostics Market, By Test, 2023 (US$ Million)
2.3. Global Cancer Diagnostics Market, By Disease Condition, 2023 (US$ Million)
2.4. Global Cancer Diagnostics Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Cancer Diagnostics Market: Competitive Analysis
3.1. Market Positioning of Key Cancer Diagnostics Market Vendors
3.2. Strategies Adopted by Cancer Diagnostics Market Vendors
3.3. Key Industry Strategies
4. Cancer Diagnostics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Cancer Diagnostics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Digital Pathology
5.3.2. Genomic Testing
5.3.3. Cancer Biomarker Tests
5.3.3.1. Circulating Tumor Cells (CTC) Tests
5.3.3.2. Prostate Specific Antigen Tests
5.3.3.3. Alpha-Fetoprotein (AFP) Test
5.3.3.4. Cancer Antigen Tests (CA 19-9 Test, CA 125 Test)
5.3.3.5. EGFR Mutation Tests
5.3.3.6. HER2 Test
5.3.3.7. BRCA Test
5.3.3.8. Others (KRAS Mutation Tests, ALK Test and CEA Tests)
5.3.4. Imaging
5.3.4.1. Positron Emission Tomography (PET) Scan
5.3.4.2. Magnetic Resonance Imaging (MRI) Scan
5.3.4.3. Computed Tomography (CT) Scan
5.3.4.4. Mammography
5.3.4.5. Ultrasound
5.3.5. Endoscopy
5.3.6. Biopsy
5.3.7. Others (Barium Enema, Bone Scan)

6. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Breast Cancer
6.3.2. Lung Cancer
6.3.3. Prostate Cancer
6.3.4. Blood Cancer
6.3.5. Colorectal Cancer
6.3.6. Ovarian Cancer
6.3.7. Liver Cancer
6.3.8. Other Cancers (Skin Cancer, Kidney Cancer, Cervical Cancer)


7. North America Cancer Diagnostics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
7.4.Cancer Diagnostics Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
7.4.1.1.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
7.4.1.2.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
7.4.1.3.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)

8. UK and European Union Cancer Diagnostics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
8.4.Cancer Diagnostics Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.4.1.1.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.4.1.2.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.4.1.3.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.4.1.4.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.4.1.5.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
8.4.1.6.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)

9. Asia Pacific Cancer Diagnostics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.3. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
9.4.Cancer Diagnostics Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.4.1.1.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.4.1.2.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.4.1.3.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.4.1.4.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.4.1.5.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
9.4.1.6.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)

10. Latin America Cancer Diagnostics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
10.3. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
10.4.Cancer Diagnostics Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
10.4.1.1.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
10.4.1.2.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
10.4.1.3.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)

11. Middle East and Africa Cancer Diagnostics Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
11.3. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
11.4.Cancer Diagnostics Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
11.4.1.1.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
11.4.1.2.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Cancer Diagnostics Market: By Test, 2022-2032, USD (Million)
11.4.1.3.2. Cancer Diagnostics Market: By Disease Condition, 2022-2032, USD (Million)

12. Company Profile
12.1. Abbott Laboratories, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Qiagen
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. F. Hoffman-La Roche
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Ambry Genetics
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. bioMeriux SA
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Becton, Dickinson & Company
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. GE Healthcare
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Siemens Healthineers
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Philips Healthcare
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Agilent Technologies, Inc.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Illumina, Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Hologic, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives